BioPorto (BIOPOR) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.249x

Based on the latest financial reports, BioPorto (BIOPOR) has a cash flow conversion efficiency ratio of -0.249x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr-15.68 Million ≈ $-2.45 Million USD) by net assets (Dkr63.01 Million ≈ $9.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BioPorto (BIOPOR) total market value for the company's overall valuation and market capitalisation.

BioPorto - Cash Flow Conversion Efficiency Trend (2000–2025)

This chart illustrates how BioPorto's cash flow conversion efficiency has evolved over time, based on yearly financial data.

BioPorto Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of BioPorto ranked by their cash flow conversion efficiency. Explore BIOPOR cash to earnings ratio to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
EcoSynthetix Inc
TO:ECO
0.014x
Biomea Fusion Inc
NASDAQ:BMEA
-0.623x
Blink Charging Co
NASDAQ:BLNK
0.011x
Transart Graphics Co Ltd
TW:8481
0.021x
Adicet Bio Inc
NASDAQ:ACET
-0.165x
Al-Salam Real Estate Investment Trust
KLSE:5269
0.068x
Rallybio Corp
NASDAQ:RLYB
0.482x
Yatas Yatak ve Yorgan Sanayi Ticaret AS
IS:YATAS
0.116x

Annual Cash Flow Conversion Efficiency for BioPorto (2000–2025)

The table below shows the annual cash flow conversion efficiency of BioPorto from 2000 to 2025. View latest BioPorto stock price today for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Dkr63.01 Million
≈ $9.86 Million
Dkr-77.07 Million
≈ $-12.06 Million
-1.223x +0.82%
2024-12-31 Dkr67.78 Million
≈ $10.60 Million
Dkr-83.58 Million
≈ $-13.08 Million
-1.233x -33.78%
2023-12-31 Dkr60.16 Million
≈ $9.41 Million
Dkr-55.46 Million
≈ $-8.68 Million
-0.922x -23.33%
2022-12-31 Dkr70.22 Million
≈ $10.99 Million
Dkr-52.48 Million
≈ $-8.21 Million
-0.747x +46.80%
2021-12-31 Dkr45.96 Million
≈ $7.19 Million
Dkr-64.58 Million
≈ $-10.10 Million
-1.405x -298.07%
2020-12-31 Dkr100.91 Million
≈ $15.79 Million
Dkr-35.62 Million
≈ $-5.57 Million
-0.353x +85.15%
2019-12-31 Dkr25.32 Million
≈ $3.96 Million
Dkr-60.16 Million
≈ $-9.41 Million
-2.376x -251.29%
2018-12-31 Dkr56.20 Million
≈ $8.79 Million
Dkr-38.01 Million
≈ $-5.95 Million
-0.676x -28.99%
2017-12-31 Dkr56.07 Million
≈ $8.77 Million
Dkr-29.40 Million
≈ $-4.60 Million
-0.524x -18.13%
2016-12-31 Dkr44.29 Million
≈ $6.93 Million
Dkr-19.66 Million
≈ $-3.08 Million
-0.444x -19.14%
2015-12-31 Dkr44.48 Million
≈ $6.96 Million
Dkr-16.57 Million
≈ $-2.59 Million
-0.373x +33.77%
2014-12-31 Dkr28.69 Million
≈ $4.49 Million
Dkr-16.14 Million
≈ $-2.52 Million
-0.563x -44.91%
2013-12-31 Dkr42.86 Million
≈ $6.71 Million
Dkr-16.64 Million
≈ $-2.60 Million
-0.388x -102.92%
2012-12-31 Dkr-1.15 Million
≈ $-179.93K
Dkr-15.28 Million
≈ $-2.39 Million
13.287x +484.76%
2011-12-31 Dkr3.94 Million
≈ $616.44K
Dkr-13.61 Million
≈ $-2.13 Million
-3.453x +14.59%
2010-12-31 Dkr3.31 Million
≈ $517.72K
Dkr-13.38 Million
≈ $-2.09 Million
-4.043x -368.99%
2009-12-31 Dkr15.41 Million
≈ $2.41 Million
Dkr-13.29 Million
≈ $-2.08 Million
-0.862x +2.57%
2008-12-31 Dkr15.50 Million
≈ $2.43 Million
Dkr-13.72 Million
≈ $-2.15 Million
-0.885x -84.47%
2007-12-31 Dkr29.45 Million
≈ $4.61 Million
Dkr-14.13 Million
≈ $-2.21 Million
-0.480x -62897.70%
2006-12-31 Dkr-17.62 Million
≈ $-2.76 Million
Dkr-13.46K
≈ $-2.11K
0.001x -83.18%
2005-12-31 Dkr-3.06 Million
≈ $-478.13K
Dkr-13.88K
≈ $-2.17K
0.005x -99.19%
2000-12-31 Dkr894.00K
≈ $139.87K
Dkr503.00K
≈ $78.70K
0.563x --

About BioPorto

CO:BIOPOR Denmark Diagnostics & Research
Market Cap
$85.98 Million
Dkr549.56 Million DKK
Market Cap Rank
#19860 Global
#87 in Denmark
Share Price
Dkr1.11
Change (1 day)
-0.45%
52-Week Range
Dkr0.84 - Dkr1.37
All Time High
Dkr7.78
About

BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination o… Read more